Stryker received FDA 510(k) clearance for the Incompass Total Ankle, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone and Infinity systems into a single, comprehensive solution for total ankle replacement.
Incompass incorporates Adaptis Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans and 100,000 clinical cases. It also offers a broad range of implant and instrumentation options to support patient-specific care.
Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company’s Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.
“Incompass reflects our commitment to redefining what’s possible in total ankle replacement,” said Adam Jacobs, Vice President and General Manager of Stryker’s Foot & Ankle business. “By building on decades of clinical experience and leveraging extensive data insights, we’re setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.”
Stryker received FDA 510(k) clearance for the Incompass Total Ankle, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone and Infinity systems into a single, comprehensive solution for total ankle...
Stryker received FDA 510(k) clearance for the Incompass Total Ankle, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone and Infinity systems into a single, comprehensive solution for total ankle replacement.
Incompass incorporates Adaptis Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans and 100,000 clinical cases. It also offers a broad range of implant and instrumentation options to support patient-specific care.
Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company’s Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.
“Incompass reflects our commitment to redefining what’s possible in total ankle replacement,” said Adam Jacobs, Vice President and General Manager of Stryker’s Foot & Ankle business. “By building on decades of clinical experience and leveraging extensive data insights, we’re setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.”
Copy to clipboard 
